Immunovia AB (publ) (STO:IMMNOV)

Market Cap	116.51M +3.8%
Revenue (ttm)	685.00K -26.4%
Net Income	-145.92M
EPS	-0.42
Shares Out	672.67M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,458,591
Average Volume	7,671,415
Open	0.1826
Previous Close	0.1820
Day's Range	0.1724 - 0.1926
52-Week Range	0.1626 - 0.9680
Beta	2.76
RSI	46.38
Earnings Date	Feb 24, 2026

About Immunovia AB

Immunovia AB (publ), a diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2007
• Employees: 13
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: IMMNOV

Financial Performance

In 2025, Immunovia AB's revenue was 685,000, a decrease of -26.42% compared to the previous year's 931,000. Losses were -145.92 million, 90.6% more than in 2024.